Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07188246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

Study acronym: BRINK
StatusRecruiting
PhasePhase 2
Started2026-01-19
View on ClinicalTrials.gov ↗

Amendment history

2026-02-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Completion date2029-01→2029-02
Start dateestimated 2025-10→confirmed 2026-01-19
Study sites2 entries, revised
St. Joseph's Health Care London Regional Cancer Program
2025-09-20
Original filing
This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy. Preliminary results from the investigators' local TRIO Trial suggest that SBRT prior to neoadjuvant chemotherapy (NAC) may result in improved response rates due to the combined effect of radiation therapy (RT) and chemotherapy. The investigators aim to augment this effect with the addition of pembrolizumab, a monoclonal antibody that binds to and blocks programmed cell death protein 1 (PD-1).
Trial Details
NCT Number NCT07188246
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive, Breast Cancer Triple Negative
Enrollment 40 participants
Start Date 2026-01-19
Primary Completion 2027-07 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-11